What a proud moment – behold the magic of cyclodextrins!
Our long-time friends and partners at Cyclarity Unveil First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol
Daniel Clemens recently presented the first data from Cyclarity Therapeutics‘ ongoing Phase I trial with UDP-003
Key highligths:
1. Safe excretion of 7KC (7-keto-cholesterol), a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine could move beyond slowing heart disease to disease-modifying plaque reversal
2. First candidate from Cyclarity’s AI Platform reinforces promise of next-generation cyclodextrins to reverse disease and protect against future accumulation of harmful molecules and aging pathologies
Cyclarity’s UDP-003 binds directly to 7KC, the root cause of plaque buildup, then facilitates urinary excretion of it. Much like removing rust from metal, this approach directly targets a key source of damage within plaque with the goal of reversing and preventing atherosclerosis, a primary underlying cause of cardiovascular disease, and does so locally within the plaque to reduce risks of unintended systemic effects.
Plaque reversal is significant because research suggests that even a 1% reduction in coronary plaque burden has been associated with up to 25% lower risk of major cardiovascular events, such as heart attack or stroke.
In parallel, they are preparing for the launch of our Phase 2 trial, expected to kick off in early 2027.
Cyclarity Therapeutics is a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease.
Read the full story here: Cyclarity Unveils First-Ever Clinical Data Demonstrating
